Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE/TSX: BLCO) reported Q2 2025 financial results with total revenue of $1.278 billion, representing a 5% increase as reported and 3% growth on a constant currency basis compared to Q2 2024. The company posted a GAAP net loss of $62 million and Adjusted EBITDA of $191 million.
By segment, Vision Care revenue grew 8% to $753 million, Surgical increased 3% to $216 million, while Pharmaceuticals remained flat at $309 million. The company has raised its full-year 2025 guidance, now projecting revenue between $5.050B - $5.150B with 5-7% constant currency growth.
Notable achievements include reaching $1 billion in trailing 12-month revenue across the dry eye portfolio and resuming full production of enVista® platform IOLs following a market return.
Bausch + Lomb (NYSE/TSX: BLCO) has announced the publication of Phase 3 study results for its LUMIFY Preservative Free redness reliever eye drops in Ophthalmology and Therapy. The study, involving 380 participants, demonstrated that the preservative-free formulation is non-inferior to the original LUMIFY in reducing ocular redness.
The clinical trial showed the new formulation delivers results in one minute and lasts up to eight hours. The study met its primary objective, with participants receiving single drops four times daily for four weeks. Both formulations demonstrated comparable safety profiles and low incidence of side effects like rebound redness when used as directed.
Bausch + Lomb (NYSE/TSX: BLCO) has launched "Eyes Tell the Story: The Impact of Dry Eye," a campaign aimed at educating the public about dry eye through personal stories, imagery, and new survey data. The initiative builds upon their 2024 "Know Your Dry Eye" educational campaign.
The company's latest survey revealed significant findings: 78% of sufferers desire more resources and education on dry eye, 62% incorrectly assume dry eye resolves itself after treatment, and 40% waited six months or more before seeking medical help. The campaign features collaboration with photographer Kayte Demont, who captured portraits of dry eye sufferers including interior designer Alvin Wayne and lifestyle blogger Brianne Manz.
According to the company, approximately 150 million U.S. adults experience occasional or frequent dry eye symptoms, with 38 million living with chronic dry eye disease. The campaign emphasizes the importance of early intervention and highlights that relief options range from over-the-counter drops to prescription treatments.
Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has scheduled two important investor events. The company will release its second-quarter 2025 financial results on Wednesday, July 30, 2025, at 8:00 a.m. ET, followed by a conference call and live webcast to discuss results and provide a business update.
Additionally, Bausch + Lomb will host an investor day on Thursday, November 13, 2025, where it plans to present a business update and showcase its innovative product pipeline. Further details about the investor day will be provided closer to the event date.
Bausch + Lomb (NYSE/TSX: BLCO) has successfully completed several significant financing transactions. The company closed an upsized offering of €675 million senior secured floating rate notes due 2031 and executed a partial credit agreement refinancing including a $2.325 billion term B loan facility and an $800 million revolving credit facility.
The notes will bear interest at three-month EURIBOR plus 3.875% per year with a 0% floor. The term B loans carry an interest rate of 4.25% for SOFR Loans and 3.25% for ABR Loans. The proceeds were used to refinance existing debt facilities and pay related expenses.
Bausch + Lomb (NYSE/TSX: BLCO) announced that CFO Sam Eldessouky will participate in the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 7:35 a.m. ET in New York City. Investors can access a live webcast of the conference through the company's Investor Relations website. Bausch + Lomb is a global eye health company focused on helping people improve their vision and quality of life.
Bausch + Lomb (NYSE/TSX: BLCO) held its 2025 Annual Meeting of Shareholders on May 21, 2025, where shareholders elected all 10 nominated directors to the board. The meeting resulted in strong approval rates for all nominees, with each director receiving over 337 million votes in favor.
Additionally, shareholders approved several other key measures including: a non-binding advisory vote on executive compensation, the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2026 Annual Meeting, and authorization for the board to determine the auditor's remuneration.